Praxis Precision Medicines Inc (PRAX)
42.55
-2.22
(-4.96%)
USD |
NASDAQ |
May 22, 16:00
42.63
+0.08
(+0.19%)
After-Hours: 20:00
Praxis Precision Medicines Cash from Investing (TTM): -86.27M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -86.27M |
December 31, 2023 | 38.95M |
September 30, 2023 | 61.59M |
June 30, 2023 | 109.55M |
March 31, 2023 | 139.44M |
December 31, 2022 | 96.89M |
September 30, 2022 | 84.46M |
Date | Value |
---|---|
June 30, 2022 | 50.06M |
March 31, 2022 | -9.06M |
December 31, 2021 | -140.52M |
September 30, 2021 | -150.69M |
June 30, 2021 | -164.24M |
March 31, 2021 | -140.01M |
December 31, 2020 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-164.24M
Minimum
Jun 2021
139.44M
Maximum
Mar 2023
-7.846M
Average
19.48M
Median
Cash from Investing (TTM) Benchmarks
Catalyst Pharmaceuticals Inc | -131.33M |
Regeneron Pharmaceuticals Inc | -4.636B |
Atossa Therapeutics Inc | -0.02M |
ADMA Biologics Inc | -5.398M |
Viking Therapeutics Inc | -641.08M |